-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JDfVDZgWyCp868+ecugRE2Lh6djPml5GUAcR/JFk2OYCyGERucDzugNFFze2OHrl tchaGhOuiR8wnwOn98i2qg== 0001104659-08-036296.txt : 20080714 0001104659-08-036296.hdr.sgml : 20080714 20080528180505 ACCESSION NUMBER: 0001104659-08-036296 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: METABASIS THERAPEUTICS INC CENTRAL INDEX KEY: 0001053221 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 CORRESP 1 filename1.htm



11119 North Torrey Pines Road

La Jolla, California 92037


May 28, 2008





Bryan J. Pitko, Esq.

Division of Corporation Finance

U.S. Securities and Exchange Commission

Mailstop 6010

100 F Street, NE

Washington, D.C.  20549



Metabasis Therapeutics, Inc.


Form S-3 Registration Statement (File No. 333-150806)


Ladies and Gentlemen:


Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on May 30, 2008 or as soon thereafter as is practicable.


The undersigned registrant hereby acknowledges that:  should the Commission or its staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; the action of the Commission or its staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and the registrant may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.


Very truly yours,






/s/ Paul K. Laikind


Paul K. Laikind, Ph.D.


President and Chief Executive Officer